Aravive (ARAV) Competitors $0.04 0.00 (0.00%) As of 08/1/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsSEC FilingsSustainabilityTrendsBuy This Stock ARAV vs. ATNFW, LBPSW, AEHAW, AIMDW, ALVOW, ACABW, BFRIW, BTMDW, BCTXW, and CALAShould you be buying Aravive stock or one of its competitors? The main competitors of Aravive include 180 Life Sciences (ATNFW), 4D pharma (LBPSW), Aesther Healthcare Acquisition (AEHAW), Ainos (AIMDW), Alvotech (ALVOW), Atlantic Coastal Acquisition Corp. II (ACABW), Biofrontera (BFRIW), biote (BTMDW), BriaCell Therapeutics (BCTXW), and Calithera Biosciences (CALA). These companies are all part of the "pharmaceutical products" industry. Aravive vs. Its Competitors 180 Life Sciences 4D pharma Aesther Healthcare Acquisition Ainos Alvotech Atlantic Coastal Acquisition Corp. II Biofrontera biote BriaCell Therapeutics Calithera Biosciences 180 Life Sciences (NASDAQ:ATNFW) and Aravive (NASDAQ:ARAV) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, profitability, media sentiment, risk, valuation and earnings. Which has better earnings and valuation, ATNFW or ARAV? 180 Life Sciences has higher earnings, but lower revenue than Aravive. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio180 Life SciencesN/AN/AN/AN/AN/AAravive$9.14M0.32-$76.32MN/AN/A Does the media refer more to ATNFW or ARAV? In the previous week, 180 Life Sciences had 2 more articles in the media than Aravive. MarketBeat recorded 2 mentions for 180 Life Sciences and 0 mentions for Aravive. 180 Life Sciences' average media sentiment score of 0.48 beat Aravive's score of 0.00 indicating that 180 Life Sciences is being referred to more favorably in the media. Company Overall Sentiment 180 Life Sciences Neutral Aravive Neutral Is ATNFW or ARAV more profitable? Company Net Margins Return on Equity Return on Assets 180 Life SciencesN/A N/A N/A Aravive N/A N/A N/A Do insiders & institutionals have more ownership in ATNFW or ARAV? 35.8% of Aravive shares are held by institutional investors. 60.4% of Aravive shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. SummaryAravive beats 180 Life Sciences on 3 of the 5 factors compared between the two stocks. Get Aravive News Delivered to You Automatically Sign up to receive the latest news and ratings for ARAV and its competitors with MarketBeat's FREE daily newsletter. Email Address Media Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ARAV vs. The Competition Export to ExcelMetricAraviveMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.95M$2.99B$5.48B$9.53BDividend YieldN/A2.43%4.73%4.09%P/E RatioN/A17.7428.8923.83Price / Sales0.32178.71371.1466.13Price / CashN/A41.9535.4557.96Price / BookN/A8.508.265.54Net Income-$76.32M-$55.06M$3.25B$259.28M7 Day PerformanceN/A-3.99%-3.73%-4.67%1 Month PerformanceN/A9.58%4.28%4.37%1 Year PerformanceN/A6.70%25.85%17.90% Aravive Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ARAVAraviveN/A$0.04flatN/AN/A$2.95M$9.14M0.0020High Trading VolumeATNFW180 Life SciencesN/A$0.01-14.0%N/A+18.6%$0.00N/A0.007News CoveragePositive NewsHigh Trading VolumeLBPSW4D pharmaN/AN/AN/AN/A$0.00$522K0.00N/AAEHAWAesther Healthcare AcquisitionN/A$0.00flatN/AN/A$0.00N/A0.002AIMDWAinosN/A$0.13-5.5%N/AN/A$0.00$106.21K0.0040Positive NewsALVOWAlvotechN/A$1.94-27.1%N/A-47.5%$0.00$585.60M0.004Positive NewsACABWAtlantic Coastal Acquisition Corp. IIN/A$0.05-0.6%N/A-35.3%$0.00N/A0.0015High Trading VolumeBFRIWBiofronteraN/A$0.19-5.0%N/A+400.0%$0.00$38.00M0.0070Positive NewsGap UpBTMDWbioteN/A$0.01-14.7%N/A-97.2%$0.00$199.38M0.00N/ABCTXWBriaCell TherapeuticsN/A$0.05+11.4%N/A-82.0%$0.00N/A0.008Positive NewsShort Interest ↑Gap DownCALACalithera BiosciencesN/A$0.00flatN/AN/A$0.00N/A0.0060 Related Companies and Tools Related Companies ATNFW Competitors LBPSW Competitors AEHAW Competitors AIMDW Competitors ALVOW Competitors ACABW Competitors BFRIW Competitors BTMDW Competitors BCTXW Competitors CALA Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ARAV) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | Sponsored379 passengers walked away from thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredI warned you about Nvidia… now look what’s happeningNvidia just got Trump’s greenlight to sell high-powered AI chips to China — and their stock surged 5% before t...Timothy Sykes | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredOne stock to replace NvidiaInvesting Legend Hints the End May be Near for These 3 Iconic Stocks One company to replace Amazon… another...InvestorPlace | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aravive, Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Aravive With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
